Rx Item-Emend Powder fosaprepitant dimeglumine 150Mg Vial 10Ml By Merck

Clinical Information
Gen. Code and Des.
66837 fosaprepitant dimeglumine INTRAVEN VIAL 150 MG
GCN and Des.
29247 fosaprepitant dimeglumine INTRAVEN VIAL 150 MG
Strength
150MG
Dose Form
VIAL (EA)
Product Category
RX Pharmaceuticals
Fine Line Class
850085008510 All Rx Products
DEA Class
NC
OMP Family

AHFS Class
56223200 NEUROKININ-1 RECEPTOR ANTAGONISTS
Active Ingredients
12535 fosaprepitant dimeglumine 265121048
Inactive Ingredients
2432 lactose 64044515
2551 polysorbates 9005645
3785 edetic acid 60004



fosaprepitant dimeglumine

EMEND - aprepitant capsule
EMEND - aprepitant
Physicians Total Care, Inc.

1 INDICATIONS AND USAGE

1.1 Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
EMEND, in combination with other antiemetic agents, is indicated for the:

prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin
prevention of nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC) [see Dosage and Administration (2.1)].
1.2 Prevention of Postoperative Nausea and Vomiting (PONV)


EMEND is indicated for the prevention of postoperative nausea and vomiting [see Dosage and Administration (2.2)].

1.3 Limitations of Use
EMEND has not been studied for the treatment of established nausea and vomiting.

Chronic continuous administration is not recommended [see Warnings and Precautions (5.5)].

2 DOSAGE AND ADMINISTRATION

2.1 Prevention of Chemotherapy Induced Nausea and Vomiting (CINV)
Capsules of EMEND (aprepitant) are given for 3 days as part of a regimen that includes a corticosteroid and a 5-HT3 antagonist. The recommended dose of EMEND is 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3.

EMEND may be taken with or without food.

EMEND (fosaprepitant dimeglumine) for Injection (115 mg) is a prodrug of aprepitant and may be substituted for oral EMEND (125 mg), 30 minutes prior to chemotherapy, on Day 1 only of the CINV regimen as an intravenous infusion administered over 15 minutes.

In clinical studies with EMEND, the following regimen was used for the prevention of nausea and vomiting associated with highly emetogenic cancer chemotherapy:

RX ITEM-Emend Powder 150Mg Vial 10Ml By
NDC 00006-3941-32 UPC/GTIN No.3-00063-94132-7 Mfg.Part No.394132

Emend Powder 150Mg Vial 10Ml By Merck
BRAND: EMEND NDC: 00006-3061-00,6306100 UPC: 3-00063-94132-7,300063941327 Merck & Co.

FOSAPREPITANT DIMEGLUMINE
Only Lic.-Physician,Pharmacy,Dentist,Drug Mfg,Dist.,Gov,Hospital,Lic.Lab,Naturalist,Naturopath,NP,Optometrist,Pharmacist,PA,Physical Therapist,Podiatrist,Research Co.,Uni.,VA,Vet & Wholesalers in scop

Buy More Save More!
Want to do Research on this Med or need a large quantity? Email Details with quantity required to:[email protected]

AmericanPharmaWholesale.com
Visit AmericanPharmaWholesale.com for over 100,000 items of Health & Beauty at Retail@Wholesale prices.